3-Hydroxyglutaric Acid

If a child or adult has unexplained movement problems, a sudden Reye-like illness after a fever, or a newborn screen that flagged a possible metabolic disorder, this is one of the tests that can settle the question. Urine 3-hydroxyglutaric acid (3-HGA) is among the most accurate single chemical fingerprints for glutaric aciduria type I, a rare but treatable inherited disease that can quietly damage a specific part of the brain called the striatum.

This is a niche test, not a general wellness marker. Most healthy people will never need it. But for the people who do need it, it is highly informative: in the original validation study, a quantitative urine measurement using a specialized stable-isotope dilution assay achieved 100% sensitivity and 100% specificity for glutaric aciduria type I, including patients whose other lab markers looked nearly normal. That degree of accuracy reflects the specific assay used and may not generalize to all laboratory methods.

What This Test Detects

3-HGA (3-hydroxyglutaric acid) is a small molecule, a hydroxylated organic acid related to glutaric acid. It is produced when the body tries to break down the amino acids lysine, hydroxylysine, and tryptophan, but cannot finish the job because a critical enzyme called glutaryl-CoA dehydrogenase (GCDH) is missing or broken. The unfinished products spill into the blood, build up in the brain, and get filtered into urine, where this test detects them.

Healthy people have low background levels of 3-HGA in urine. In people with glutaric aciduria type I, levels can be many times higher, though some patients (low excretors) have only modest elevations. Results are reported relative to creatinine to adjust for how concentrated the urine sample is.

Glutaric Aciduria Type I

Glutaric aciduria type I, often called GA-I or GA1, is an inherited disorder caused by two faulty copies of the GCDH gene. Without working GCDH enzyme, the body cannot finish breaking down lysine, hydroxylysine, and tryptophan, and the byproducts accumulate. The brain is especially vulnerable. Children with untreated GA-I are at high risk of acute brain crises, with most occurring in the first 24 months and the vulnerable period extending up to age 6 years, often triggered by a fever, infection, or surgery. These crises can cause sudden, severe, lifelong movement disorders called dystonia.

With early detection through newborn screening, careful diet, carnitine supplementation, and aggressive treatment during illness, many children avoid serious brain damage. Without it, the outcomes are often devastating. This is why a precise diagnosis matters so much, and why 3-HGA is the test that often makes the difference.

High Excretors and Low Excretors

GA-I patients fall into two biochemical groups. High excretors dump large amounts of glutaric acid and 3-HGA into urine, making the diagnosis obvious on a standard organic acid panel. Low excretors are trickier: their urinary glutaric acid can be normal or only slightly elevated, and they can slip through screening that relies on glutaric acid or blood acylcarnitine alone.

Quantitative 3-HGA is the marker that closes most of this gap. Even in low excretors, 3-HGA is usually noticeably elevated compared to controls, which is why guidelines emphasize measuring it directly rather than relying on glutaric acid alone. Rare exceptions exist: a 2023 case report documented a confirmed low-excretor GA-I patient with absent 3-HGA on routine urine organic acid analysis, so even this marker is not absolutely infallible across all methods.

Why This Test Beats Glutaric Acid Alone

Both glutaric acid and 3-HGA pile up when GCDH is broken, but 3-HGA is more reliable as a diagnostic. In the original validation cohort, quantitative 3-HGA by stable-isotope dilution achieved 100% sensitivity and 100% specificity. Glutaric acid alone misses low excretors. Blood glutarylcarnitine, the marker used in newborn screening, can also be normal or borderline in low-excretor cases. 3-HGA closes most of this blind spot, though rare low-excretor cases with absent 3-HGA on routine analysis have been described.

Source: Barić et al. 1999; Busquets et al. 2000; Spenger et al. 2021; Wongkittichote et al. 2023. What this means for you: if there is any clinical suspicion of GA-I, quantitative 3-HGA should be part of the workup, even if glutaric acid and newborn screening looked fine.

Brain Injury Risk When Levels Are Elevated

Persistently elevated 3-HGA is not just a lab finding. It reflects how much toxic byproduct is building up in the brain. Brain imaging studies in GA-I patients have shown that the high-excretor phenotype is linked to greater cerebral accumulation of these metabolites and more nerve cell damage. The high-excretor phenotype has also been identified as the major risk factor for cognitive impairment in a national follow-up study of GA-I patients.

High excretors are also more prone to subdural hematomas, a kind of bleeding around the brain that can be mistaken for child abuse, and may have higher rates of subtle nerve damage in the limbs. The clinical picture is shaped by how much of this metabolite the body is producing.

Other Conditions With Mildly Elevated Levels

Not every elevation in 3-HGA points to GA-I. Some patients with mildly elevated 3-HGA turn out not to have GCDH deficiency on genetic and enzyme testing. Related metabolic disorders can produce overlapping organic acid patterns, including 3-methylglutaconic aciduria, 3-hydroxy-3-methylglutaric aciduria, and short-chain acyl-CoA dehydrogenase deficiency. In one study, autistic children with atopic dermatitis had higher urinary 3-HGA than autistic children without it, though the link did not survive statistical adjustment.

This is why a single isolated elevation should not be the end of the story. The full urine organic acid pattern, glutarylcarnitine, enzyme activity, and gene testing are usually all needed to land on a specific diagnosis.

Reconciling Mild Elevations That Do Not Mean GA-I

It can feel contradictory that elevated 3-HGA can sometimes mean GA-I and other times mean something else entirely. Think of this marker less as a switch and more as a smoke signal. The same chemical can come from different fires: the classic GA-I pathway, related but distinct enzyme defects, or even a borderline finding with no clear cause. The size of the elevation, the pattern of other organic acids, and confirmatory enzyme or genetic testing are what separate one cause from another.

When Results Can Be Misleading

• Single-sample variability: urinary organic acids show meaningful day-to-day variation within the same person. A borderline result on one sample may look normal or clearly abnormal on a fresh repeat collection.
• Sample handling and assay method: routine gas chromatography mass spectrometry can miss low-excretor cases, and rare low-excretor patients have been reported with absent 3-HGA on routine analysis. Quantitative stable-isotope dilution assays are far more sensitive and should be requested when GA-I is in the differential.
• Concentration of the urine: 3-HGA is reported relative to creatinine to adjust for how dilute the sample is. Very dilute or very concentrated urine can still complicate interpretation.
• Newborn screening blind spots: a normal newborn blood screen does not rule out GA-I. False negatives have been documented, particularly in low-excretor patients, so urinary 3-HGA may still be warranted when clinical suspicion is high.

Tracking Levels Over Time

For most people who order this test, a single result is enough to either confirm or rule out GA-I when combined with confirmatory genetic and enzyme testing. For someone already diagnosed with GA-I, repeat urine 3-HGA testing serves a different purpose: it tracks how well dietary and supplemental therapy are working over time, and helps catch metabolic decompensation early. Current GA-I management guidelines recommend regular biochemical monitoring by a metabolic specialist without specifying an exact cadence for urinary organic acids; in clinical practice, testing every 3 to 6 months during early childhood and at least annually thereafter is a common approach, with more frequent checks during illness or therapy changes.

If your first result is borderline or unexpectedly elevated and you are otherwise healthy, the most important next step is a repeat collection on a fresh sample, not a leap to a specific diagnosis. Single elevations in organic acids are common enough that confirmation is the standard approach.

What to Do With an Abnormal Result

An elevated urine 3-HGA result should trigger a coordinated workup, not a wait-and-watch approach. The standard next steps include a full quantitative urine organic acid panel, blood acylcarnitine analysis to look at glutarylcarnitine (C5DC), and referral to a specialist metabolic center. Confirmatory testing usually involves GCDH gene sequencing and, when needed, enzyme activity assays on cultured cells.

Brain imaging, particularly MRI, is often added to look for the characteristic frontotemporal changes and striatal injury seen in GA-I. For asymptomatic biological relatives of a confirmed patient, genetic counseling and targeted testing are appropriate. The point of the workup is not just to confirm a label, but to start dietary lysine restriction, carnitine supplementation, and an emergency illness protocol that can prevent permanent brain damage.